An Australian biotechnology company has contributed to a world-first diagnostic test for bladder cancer that could save patients a lot of pain and money.
Melbourne-based Sienna Cancer Diagnostics’ lead product is the anti-hTERT SCD-A7 antibody that can be used in diagnostic tests to detect telomerase, an enzyme associated with around 90 per cent of human cancers.
US pathology firm Bostwick Laboratories will use the SCD-A7 antibody in the world’s first stain test to detect telomerase for bladder cancer.
“Ultimately, this could improve the diagnosis of bladder cancer and leading to better patient outcomes and healthcare cost savings,” Sienna managing director Dr Kerry Hegarty said.